Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy
Qingqing Pan, Yao Lu, Xie Li, et al.
Molecular Pharmaceutics (2023) Vol. 20, Iss. 2, pp. 829-852
Closed Access | Times Cited: 21

Showing 21 citing articles:

Nano-enabled colorectal cancer therapy
Qingqing Pan, Fan Xi, Li Xie, et al.
Journal of Controlled Release (2023) Vol. 362, pp. 548-564
Closed Access | Times Cited: 22
Formulation and Evaluation of Lipid/Soluplus-Stabilized Nanocrystals of Paclitaxel and Bosutinib for a Synergistic Effect in Non-Small Cell Lung Cancer Therapy
Manish Kumar, Pooja Goswami, Abhishek Jha, et al.
Molecular Pharmaceutics (2025)
Closed Access
Repositioning Cannabinoids and Terpenes as Novel EGFR-TKIs Candidates for Targeted Therapy Against Cancer: A virtual screening model using CADD and biophysical simulations
Ossama Daouı, Suraj N. Mali, Kaouakeb Elkhattabi, et al.
Heliyon (2023) Vol. 9, Iss. 4, pp. e15545-e15545
Open Access | Times Cited: 16
Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review
Fariba Peytam, Zahra Emamgholipour, Ali Mousavi, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106831-106831
Closed Access | Times Cited: 10
Antineoplastic drugs inducing cardiac and vascular toxicity – An update
Serena Barachini, Sandra Ghelardoni, Zoltán V. Varga, et al.
Vascular Pharmacology (2023) Vol. 153, pp. 107223-107223
Closed Access | Times Cited: 9
SUMOylation of AnxA6 facilitates EGFR-PKCα complex formation to suppress epithelial cancer growth
Zenghua Sheng, Xu Cao, Yanan Deng, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 8
Design of gefitinib-loaded PLGA microspheres via microfluidics for lung cancer
Ruohan Huang, Hui Zhang, Lulu Lv, et al.
Materials & Design (2023) Vol. 234, pp. 112336-112336
Open Access | Times Cited: 5
Recombinant retroviral vectors that express EGF, TGF alpha, NRG2 beta, and the NRG2 beta Q43L mutant v2
Ella Wilson
(2024)
Open Access | Times Cited: 1
Targeting EGFR by Newer 1-(3,5-Bis((E)-4-hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl)-2-((substituted phenyl)amino)ethan-1-one Analogues for the Treatment of Cancer: Synthesis, In-vitro and In-silico Studies
Menshawy A. Mohamed, Abuzer Ali, Amena Ali, et al.
Journal of Molecular Structure (2024) Vol. 1315, pp. 138826-138826
Closed Access | Times Cited: 1
Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma
Hanwen Lu, Bingchang Zhang, Yuanyuan Xie, et al.
Investigational New Drugs (2023) Vol. 41, Iss. 4, pp. 564-578
Closed Access | Times Cited: 3
Identification of Dual-Target Inhibitors for Epidermal Growth Factor Receptor and AKT: Virtual Screening Based on Structure and Molecular Dynamics Study
Hanyu Yang, Zhiwei Zhang, Qian Liu, et al.
Molecules (2023) Vol. 28, Iss. 22, pp. 7607-7607
Open Access | Times Cited: 3
Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer
Pelinsu Korucu Aktas, İpek Baysal, Samiye Yabanoğlu‐Çiftçi, et al.
International Journal of Pharmaceutics (2023) Vol. 650, pp. 123703-123703
Closed Access | Times Cited: 3
Targeting the Bcr-Abl Oncoprotein in Leukemia: Molecular Docking Analysis and Toxicity Prediction of Potential Therapeutic Candidates
Ivan Vito Ferrari
(2024)
Open Access
Signaling Pathways in Drug Development
Habab Ali Ahmad, Kiran Seemab, Fazal Wahab, et al.
Pharmaceutical science. (2024)
Open Access
Gefitinib Induces Apoptosis in NSCLC Cells by Promoting Glutaminolysis and Inhibiting the MEK/ERK Signaling Pathway
Yakun Zhang, Haixin Liu, Xianyan Liu, et al.
Discovery Medicine (2024) Vol. 36, Iss. 183, pp. 836-836
Open Access
Schisandrin C inhibits AKT1-regulated cell proliferation in A549 cells
Zhisen Wang, Shengyang Xie, Li Li, et al.
International Immunopharmacology (2024) Vol. 142, pp. 113110-113110
Open Access
Synthesis, cytotoxicity and molecular docking of novel quinazoline-4(3H)-thione derivatives as EGFR-TKIs
Alyaa S. Abdel Halim, Marwa S. Salem, Selima Ali Almabrook, et al.
Journal of the Indian Chemical Society (2024), pp. 101388-101388
Closed Access
Recent advances in phototherapeutic nanosystems for oral cancer
Qingqing Pan, H. B. Tang, Xie Li, et al.
Journal of Materials Chemistry B (2024)
Closed Access
Metastasis suppressor genes in clinical practice: are they druggable?
Irwin H. Gelman
Cancer and Metastasis Reviews (2023) Vol. 42, Iss. 4, pp. 1169-1188
Closed Access | Times Cited: 1
Screening for EGFR and AKT dual-target inhibitors
Han-Yu Yang, Zhiwei Zhang, Jie Yu, et al.
Research Square (Research Square) (2023)
Open Access
Supramolecular fluorescence sensor array used for the analysis of tyrosine kinase inhibitors in biological fluids and cell imaging
Hong-Ling Yi, Ru-Pei Yang, Qing Tang, et al.
Analytica Chimica Acta (2023) Vol. 1287, pp. 342124-342124
Closed Access
Page 1

Scroll to top